盟科药业(688373.SH)：MRX-5在美国获得开展临床试验许可

Core Viewpoint - MicuRx Pharmaceuticals, Inc., a wholly-owned subsidiary of Amgen Pharmaceuticals (688373.SH), has received approval from the U.S. Food and Drug Administration (USFDA) to conduct clinical trials for its self-developed antibacterial drug MRX-5 tablets in the United States, targeting non-cavitary lung disease caused by Mycobacterium abscessus complex infections [1]. Group 1 - The clinical trial application for MRX-5 has been approved by the USFDA [1] - The drug is indicated for the treatment of non-cavitary lung disease caused by Mycobacterium abscessus complex infections [1]